Global Nearshore Footprint Weiss-Aug MedPharma has expanded manufacturing into Mexico and the Americas, enabling nearshore production for US medical device and pharmaceutical brands. This footprint supports regional supply chain resilience, shorter lead times, and easier regulatory alignment for US customers. ISO certified facilities reinforce their commitment to quality and compliance.

End to End Capabilities The company offers vertical integration from engineering design and development through precision machining, injection molding, metal stamping and value added assembly. This approach reduces supplier complexity, speeds time to market, and improves traceability for regulated industries. The ISO focus underpins ability to meet high quality standards.

OEM Track Record Weiss-Aug has an established track record with major OEMs including Medtronic, and has collaborated with R&D teams on surgical instrument components. This history supports its credibility for long term design to manufacture partnerships. It positions the company well to pursue new OEM programs in instrument components and assemblies.

Growth Momentum The Weiss-Aug Group reorganized to launch Weiss-Aug MedPharma in 2025 and promoted Elisabeth Weissenrieder-Bennis to President. This signals a growth trajectory and receptiveness to new programs, capacity expansion or co development with customers. It creates an opening to discuss capacity needs and program scale.

Tech and Compliance Edge The operation leverages design and manufacturing software including PTC Creo, SAP Crystal Reports and Microsoft Project, alongside ISO certified processes and traceability. This supports efficient program management, rigorous quality control and scalable production for regulated medical devices and pharmaceuticals.